Outcomes of Patients with
lung cancer
overall survival
time on treatment
tyrosine kinase inhibitors
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
03
2022
accepted:
27
05
2022
entrez:
23
6
2022
pubmed:
24
6
2022
medline:
24
6
2022
Statut:
epublish
Résumé
Although first- and second-generation EGFR TKIs are considered first-line treatment in EGFRm+ NSCLC, most patients develop resistance and progress, commonly, EGFR This multicenter retrospective study utilized data from the Malaysian Lung Cancer Registry that actively registers all lung cancer patients ≥18 years, with primary lung cancer confirmed histologically or cytologically. All patients diagnosed with advanced stages (ie stages IIIB, IIIC and IV) Of 406 patients with In the real-world, the management of
Sections du résumé
Background
UNASSIGNED
Although first- and second-generation EGFR TKIs are considered first-line treatment in EGFRm+ NSCLC, most patients develop resistance and progress, commonly, EGFR
Methods
UNASSIGNED
This multicenter retrospective study utilized data from the Malaysian Lung Cancer Registry that actively registers all lung cancer patients ≥18 years, with primary lung cancer confirmed histologically or cytologically. All patients diagnosed with advanced stages (ie stages IIIB, IIIC and IV)
Results
UNASSIGNED
Of 406 patients with
Conclusion
UNASSIGNED
In the real-world, the management of
Identifiants
pubmed: 35733510
doi: 10.2147/CMAR.S364713
pii: 364713
pmc: PMC9208817
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1995-2005Informations de copyright
© 2022 How et al.
Déclaration de conflit d'intérêts
CKL has received research grants and honoraria from Astra Zeneca, Boehringer Ingelheim, MSD, Novartis, Pfizer, Roche and Zuellig Pharma. HHH has received research grants and honoraria from Astra Zeneca, EISAI, MSD, Novartis and Tessa Therapeutics; AB science, AdipoLab, Arcus Bioscience. GFH has received research grants and honoraria from AB Science, Arcus Biosciences, Ipsen, Astellas, Astra Zeneca, Eli Lily, Boehringer Ingelheim, BMS, MSD, MIRARI Therapeutics, Novartis, Pfizer, Regeneron, Roche and Tessa Therapeutics, respectively. LMT has received honoraria from Astra Zeneca, Boehringer Ingelheim, Roche, MSD and Pfizer. The other authors have no conflicts of interest to declare in this work.
Références
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
J Biomed Sci. 2013 Apr 16;20:22
pubmed: 23590575
J Thorac Dis. 2011 Mar;3(1):10-8
pubmed: 22263058
Onco Targets Ther. 2017 Sep 06;10:4347-4354
pubmed: 28919784
Clin Cancer Res. 2013 Apr 15;19(8):2240-7
pubmed: 23470965
Med J Malaysia. 2016 Jun;71(Suppl 1):70-78
pubmed: 27801389
Lancet Oncol. 2011 Aug;12(8):735-42
pubmed: 21783417
Oncol Ther. 2018 Dec;6(2):203-215
pubmed: 32700028
Lung Cancer. 2018 Mar;117:14-19
pubmed: 29496250
Mol Clin Oncol. 2018 Feb;8(2):246-249
pubmed: 29399354
Asian Pac J Cancer Prev. 2014;15(1):321-6
pubmed: 24528049
J Natl Compr Canc Netw. 2017 Apr;15(4):504-535
pubmed: 28404761
JTO Clin Res Rep. 2020 Mar 10;1(2):100022
pubmed: 34589929
J Clin Oncol. 2017 Apr 20;35(12):1288-1296
pubmed: 28221867
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
BMC Cancer. 2019 Sep 9;19(1):896
pubmed: 31500587
Drug Des Devel Ther. 2019 Sep 06;13:3187-3198
pubmed: 31564835
J Thorac Oncol. 2009 May;4(5):568-77
pubmed: 19357537
Ann Oncol. 2016 Sep;27(suppl 5):v1-v27
pubmed: 27664245
BMC Cancer. 2020 Apr 28;20(1):356
pubmed: 32345265
J Clin Oncol. 2020 Jan 10;38(2):124-136
pubmed: 31411950
Lancet Oncol. 2010 Feb;11(2):121-8
pubmed: 20022809
Eur Respir J. 2016 May;47(5):1502-9
pubmed: 27030679
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Cochrane Database Syst Rev. 2016 May 25;(5):CD010383
pubmed: 27223332
J Clin Oncol. 2020 Jan 10;38(2):115-123
pubmed: 31682542
Front Oncol. 2020 Sep 04;10:1481
pubmed: 33014788
Mol Cancer. 2018 Feb 19;17(1):38
pubmed: 29455650